About The Study: In this umbrella review of meta-analyses, evidence for most noncardiometabolic outcomes associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was of lower certainty. Potential safety signals were observed for gastrointestinal adverse events, while suggested protective associations with respiratory diseases and serious infections require further confirmation.
Corresponding Authors: To contact the corresponding authors, email Yongze Li, PhD, (yzli87@cmu.edu.cn) and Qiqiang Guo, PhD, (qqguo@cmu.edu.cn).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2026.4722)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.4722?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=033126
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open